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clinical variables and SES. The SES variable was derived from prin-
ciple component analysis of census block level CCR data linked to cen-
sus data addressing seven major indicators of SES and is divided into 
ﬁve quintiles. Univariate survival analyses were conducted using the 
Kaplan-Meier method. Multivariate survival analyses were performed 
using Cox proportional hazards ratios.
Results: 19,702 incident cases of stage I NSCLC were analyzed. 
Low SES was found in a greater proportion of African-American and 
Hispanic patients, and was signiﬁcantly associated with more males, 
unmarried patients, IB disease, squamous cell histology, poorly-differ-
entiated tumors, fewer surgical resections performed, and less overall 
treatment received. Reasons for no surgery were primarily associated 
with low SES and unmarried status. In multivariate analysis, unmarried 
status carried an independent increased risk of mortality (vs. married; 
HR = 1.18, 95% CI = 1.12 to 1.23). Low SES was also identiﬁed to 
independently carry increased mortality risk. Each incremental increase 
in SES quintile was associated with statistically signiﬁcant decrease 
hazard of death (SES 2 vs. SES1, HR = 0.91, 95%CI = 0.85 to 0.98; 
SES3 vs. SES 1, HR = 0.90, 95% CI = 0.84 to 0.97; SES4 vs. SES1, 
HR = 0.83, 95% CI = 0.77 to 0.89; SES5 vs. SES1, HR = 0.78, 95% CI 
= 0.72 to 0.84). African-American race was not an independent poor 
prognostic factor for survival after adjustment for SES or marital status 
while Hispanic race was not an independent poor prognostic factor 
after adjustment for surgical treatment.
Conclusion: Low SES is an independent poor prognostic factor for 
survival in stage I NSCLC, and is independent of race, marital status, 
surgery and other poor prognostic factors. Mitigating the effects of low 
SES will likely improve early stage NSCLC survival. 
A=SES1(lowest), B=SES2(low), C=SES3, D=SES4(high), E=SES5(highest)
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Background: In high-risk subjects low-dose sCT initially showed a 4-
fold increase in the detection rate of neoplastic nodules in comparison 
with chest-X-ray. However, two recent papers (I-ELCAP Investigators 
NEJM 2006; 355:1763-1771 and Bach PB et al. JAMA 2007; 297:953-
961) led to controversial results about the efﬁcacy of sCT in improving 
overall survival of lung cancer and in addition no information about 
mortality reduction are still available from any randomized trial. Sub-
jects and Methods: From April to December 2001, 520 asymptomatic 
volunteers aged ≥ 55 years with a history of cigarette smoking ≥ 20 
packs-year and of no previous cancer received annually chest sCT for 5 
consecutive years. 
Results: At baseline 73% were male, median age was 59 years and 
91% current smokers. At baseline sCT 127 subjects (24.5%) had nod-
ules <5 mm while nodules ≥5 mm were detected in 114 (22%); the size 
of lung nodules ranged from 5 to 9.9 mm in 81.5% of the cases. The % 
of nodules worth of additional investigation varied over time (2nd yr: 
6%; 3rd yr: 5%; 4th yr: 11%; 5th yr: 11%). Five (1%) cases of LC were 
detected during the ﬁrst year (3 stage I) and in two additional resec-
tions an atypical adenomatous hyperplasia was found. Three new cases 
of thoracic cancers were detected in the second and third year. In the 
fourth year, ﬁve lung cancer (one unresectable stage IIIB) and a thymic 
carcinoma were detected. In the ﬁfth year 4 new cases (2 surgically 
resected) and a renal cancer were diagnosed. One interval case was 
detected during the third year. Following the end of the study two new 
cancers were detected (both negative for nodules at the last screening 
sCT), one resected (squamous carcinoma, stage IA, asymptomatic) and 
a symptomatic limited disease small cell lung cancer. For these 2 cases 
the interval between the last screening sCT and the diagnosis is 16 and 
16.8 months, respectively. Drop-out rate in the ﬁrst year was 25 (2nd yr 
22, 3rd yr 18 and 4th yr 24). During the 5-year screening period 31,5% 
of subjects quit smoking but, of these, 8% started again to smoke dur-
ing the course of the study. As March 2006, 17 out of 25 diagnosed 
cancer are still alive, with only one case (stage IIIA) with progression 
of disease. The median survival time for surgically resected cases who 
already died (n=6, including two cases in pathological stage I) is 25 
months, and 1,6 months for the case of thymic carcinoma (4 deaths 
were cancer related). 
Conclusion: Our study conﬁrmed the potential of sCT in the early 
detection of lung cancer. Evidence from ongoing randomised trials is 
needed to support the routine use of sCT for early detection of LC. A 
program of smoking cessation is strongly recommended for further 
studies. Currently a conservative attitude should be encouraged. 
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Survivin is an apoptosis inhibitor and plays an important role in the 
development and progression of cancer. Polymorphisms in the survivin 
gene may inﬂuence survivin production or activity, thereby modulating 
susceptibility to lung cancer. To test this hypothesis, we screened for 
